Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Genomic Health (NASDAQ: GHDX)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx Pharmaceutical (RAREResearch Report) and Genomic Health (GHDXResearch Report).

Ultragenyx Pharmaceutical (RARE)

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Ultragenyx Pharmaceutical yesterday and set a price target of $75.00. The company’s shares closed last Monday at $39.86, close to its 52-week low of $37.44.

According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 4.7% and a 45.9% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $75.80 average price target, an 87.0% upside from current levels. In a report released yesterday, Cowen & Co. also reiterated a Buy rating on the stock with a $62.00 price target.

See today’s analyst top recommended stocks >>

Genomic Health (GHDX)

Needham analyst Stephen Unger maintained a Hold rating on Genomic Health yesterday. The company’s shares closed last Monday at $65.41.

According to TipRanks.com, Unger is a 4-star analyst with an average return of 10.0% and a 58.8% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Thermo Fisher, and PerkinElmer.

Genomic Health has an analyst consensus of Moderate Buy, with a price target consensus of $130.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.